Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Mini Review Volume 5 Issue 7

Mission-oriented Research Leads Frequently to a Product for Industry

GP Talwar1*, Jagdish C Gupta1, SA Zaheer2, Shripad Patil3, Avi K Bansal3, Dipankar Nandi4, Bakulesh Khamar5, Somesh Gupta6, S Puruswani1, Hemant K Vyas1 and Krishna Ella7

1Talwar Research Foundation, New Delhi, India
2Department of Dermatology, Max Multi Speciality Centre, New Delhi, India
3National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, Uttar Pradesh, India
4Department of Biochemistry, Indian Institute of Science, Bangalore, Karnataka, India
5Cadila Pharmaceuticals Ltd, Ahmedabad, India
6Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
7Bharat Biotech International Ltd, Hyderabad, Telangana, India

*Corresponding Author: GP Talwar, Director Research, Talwar Research Foundation, New Delhi, India.

Received: May 04, 2021; Published: June 23, 2021

Abstract

This article reviews research which we undertook to combat Leprosy, of which the largest number of patients are in India. We had to learn first why a person becomes victim to this disease while more than 98% of us are immune to it. The defect is their inability to react to some key antigens of M. leprae. Having found that, the next issue was whether we can do anything to overcome this defect.

We developed a vaccine against Leprosy which is based on a cultivable, non-pathogenic mycobacteria originally coded as Mw. The gene sequence of Mw has been determined and it has been named as Mycobacterium indicus pranii (MIP), Pran is my family name and nii, the National Institute of Immunology from where trials were carried out.

Heat killed MIP given as adjunct to standard drugs expedites recovery of patients. It also renders a high percentage of multibacillary patients Lepromin positive from otherwise permanent Lepromin negativity status. Patients treated with MIP recover free of ugly blemishes which Drugs alone fail to achieve.

MIP is also effective in treatment of Category II, Difficult to treat tuberculosis patients. It is a potent invigorator of immune response and enhances significantly antibody titres of the anti-hCG vaccine under development for control of pregnancy. At the All India Institute of Medical Sciences, New Delhi, it has been used for curing ugly ano-genital warts.

Keywords: Mycobacteria; Mycobacterium indicus pranii; WHO

References

  1. Talwar GP. “An immunotherapeutic vaccine for multibacillary leprosy”. International Reviews of Immunology 3 (1999): 229-249.
  2. Talwar GP. “Leprosy is in principle eradicable – a possible approach”. Current Science 106 (2014): 1344-1345.
  3. Gupta S., et al. “Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano-genital warts: an open label pilot study”. Journal of the European Academy of Dermatology and Venereology 22 (2008): 1089-1093.
  4. Kumar P., et al. “Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial”. JAMA Dermatology 150 (2014): 1072-1078.
  5. Singh S., et al. “Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts”. Indian Journal of Dermatology, Venereology and Leprology 80 (2014): 509-514.
  6. Meena JK., et al. “Intralesional immunotherapy with Mycobacterium w vaccine in patients with multiple cutaneous warts: uncontrolled open study”. Dermatology 149 (2013): 237-239.
  7. Chandra S., et al. “A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral warts”. Indian Journal of Dermatology, Venereology and Leprology 85 (2019): 355-366.
  8. Purswani S., et al. “Mycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin”. Journal of Reproductive Immunology 91 (2011): 24-30.
  9. Sehgal IS., et al. “A randomised trial of Mycobacterium w in critically ill patients with COVID-19 (ARMY-1)”. ERJ Open Research (2021).
  10. Ingale A., et al. “Role of Mycobacterium w for the treatment of Covid-19: An Observational study”. Journal of the Associations of Physicians of India 69 (2021): 19-22.

Citation

Citation: GP Talwar., et al. “Mission-oriented Research Leads Frequently to a Product for Industry". Acta Scientific Pharmaceutical Sciences 5.7 (2020): 159-163.

Copyright

Copyright: © 2020 GP Talwar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US